SGLT-2 inhibitors can target the EAT of left atrial and coronary artery to treat and prevent atrial fibrillation and coronary artery disease by reducing visceral fat inflammation and increasing free fatty acid oxidation [50]. The gene discussed is SLC5A2; the disease is atrial fibrillation.